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Background
Impaired extinction of fear is a hallmark of a variety of
disabling anxiety disorders including panic disorder,
post-traumatic stress disorder, social anxiety disorder
and specific phobias. Therapeutic interventions that
reverse deficits in fear extinction represent a tractable
approach to treating these disorders. We recently
revealed that 129S1/SvImJ (129S1) mice are unable to
extinguish learned fear responses following ‘normal’ fear
conditioning, establishing these mice as a clinically rele-
vant model to identify extinction-facilitating targets.
Methods
129S1 mice were subjected to multi-trial ‘normal’ and
‘weak’ cued fear conditioning/extinction paradigms and
novel treatment strategies to rescue deficient extinction
were tested.
Results
Results revealed that ‘weak’ fear conditioning permitted
fear reduction during massed extinction training in
129S1 mice, but also revealed a specific deficiency in
extinction memory consolidation/retrieval. Rescue of this
impaired extinction consolidation/retrieval was achieved
with D-cycloserine (N-methly-D-aspartate partial ago-
nist) or MS-275 (histone deacetylase (HDAC) inhibitor),
applied after extinction training. We next examined the
ability of different drugs and non-pharmacological
manipulations to rescue the extreme fear extinction defi-
cit in 129S1 following ‘normal’ fear conditioning with the
ultimate aim to produce low fear levels in extinction
retrieval tests. Results showed that rescue of both
impaired extinction acquisition and deficient extinction
consolidation/retrieval was achieved with prior extinction
training administration of valproic acid (a GABAergic
enhancer and HDAC inhibitor) or AMN082 [metabotro-
pic glutamate receptor 7 (mGlu7) agonist], while MS-275
or PEPA (AMPA receptor potentiator) failed to affect
extinction acquisition in 129S1 mice. Lastly, deep brain
stimulation (DBS) by applying high frequency stimulation
to the nucleus accumbens (ventral striatum) during
extinction training, indeed significantly reduced fear dur-
ing extinction retrieval compared to sham stimulation
controls.
Conclusions
Collectively, these data identify potential beneficial
effects of various drug treatments and DBS, including
those with HDAC inhibiting or mGlu7 agonism proper-
ties, as adjuncts to facilitate the outcome of exposure-
based therapies for anxiety disorders.
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